Market Signal Briefing

SoftBank Group shares tumbled to a 2½-month low on Tuesday, extending a sharp two-day selloff triggered by concerns that Alphabet's latest Gemini artificial intelligence model could intensify competitive pressure on OpenAI — one of the Japanese conglomerate's most important investments. The stock fell as much as 11% in Tokyo, following a 10.

Facebook parent Meta is in discussions with Alphabet's Google to spend billions on using Google's AI chips in its data centers from 2027 and to rent chips from Google Cloud by next year, The Information reported on Monday.

These companies offer significant long-term upside.

The emerging opportunities in artificial intelligence (AI) and quantum computing could spell life-changing returns for investors. The best stocks in these industries are going to be volatile, but that is par for the course for high-growth companies that can deliver monster returns over time.

Let's take a look at three high-growth stocks to buy before the end of the year.

Image source: Getty Images.

1. Palantir Technologies
Over the last three decades, the growth of the internet, e-commerce, and cloud computing has created tremendous wealth for those who invested early in the leading stocks in these industries. AI promises to be the next industry that will create lasting wealth for investors. Palantir Technologies (PLTR +4.88%) is a leading AI software company that could change the fortunes of patient investors who hold shares for the long term.

Palantir is a rare breed. It's seeing robust revenue growth, which came in at 63% year over year in the recent quarter. But what's most remarkable is its profitability. Despite generating less than $4 billion in trailing-12-month revenue, Palantir has achieved a Rule of 40 score of 114 (revenue growth plus adjusted operating profit margin). This is rare for a company of this size, but it's also why the stock trades at a high multiple of sales and earnings. It has a long runway of growth and is already generating margins typically reserved for large, mature software companies.

Today's Change

(

4.88

%) $

7.55

Current Price

$

162.40

Palantir is earning such a high margin on its revenue because it is providing businesses with significant value. It organizes a company's data and makes sense of it using large language models. Major companies are willing to spend a premium to use its software because Palantir is not just selling AI models, it is selling margin expansion. One telecom company expects to save hundreds of millions of dollars using Palantir.

Palantir's deal momentum is accelerating. Companies are increasingly signing larger deals, with the total contract value for U.S. commercial transactions surging 342% year over year in the last quarter. Analysts project Palantir's revenue and free cash flow to grow at approximately 40% annually through 2029. That level of growth should drive further market-beating returns for investors.

2. Innodata
Innodata (INOD +10.63%) benefits from the growing demand for high-quality data to train AI models. It's a classic pick-and-shovel play in the AI market, offering robust growth prospects.

Today's Change

(

10.63

%) $

5.47

Current Price

$

56.93

The company's full-year revenue for 2025 is expected to increase by 45%. Its third-quarter revenue growth came in at 20% year over year, down from the higher rates reported earlier in the year. This highlights one drawback of Innodata's business model. Quarterly revenue growth can be inconsistent due to the timing of when a company uses its services.

However, the long-term trend indicates significant upside. Management noted its deal momentum remains strong, with revenue from six of its largest customers set to grow "quite substantially" next year, as CEO Jack Abuhoff explained.

Innodata's competitive advantage in the data solutions market is built on trust. Relationships with its large customers are accelerating based on Innodata's ability to deliver optimal outcomes. Big tech is banking its future on AI, and it trusts Innodata to provide quality data to improve its models.

The stock trades at 40 times next year's earnings estimate, down from the recent 70 forward earnings multiple. The recent dip is an ideal opportunity to consider buying a few shares.

Image source: Getty Images.

3. IonQ
Quantum computing is an early-stage technology with enormous potential to solve complex problems, including the discovery of new medical treatments. IonQ (IONQ +12.49%) has been investing in quantum computing technology for over 25 years, making it a leader that is now experiencing accelerating revenue growth.

IonQ saw its revenue surge 222% year over year in the recent quarter. It is executing well on expanding the commercialization of its technology by bringing its new Tempo quantum computer to market ahead of schedule.

Today's Change

(

12.49

%) $

5.21

Current Price

$

46.92

The company hasn't yet turned a profit, but it is successfully raising capital to fund its investments, signaling growing interest from institutional investors. IonQ has a robust patent portfolio, positioning it well to become a leader in this rapidly growing market.

Even after the recent pullback, the shares remain expensive, trading at 75 times next year's revenue estimate. However, as management noted on the Q3 earnings call, they are just scratching the surface of their potential. Just buying a small position as part of a diversified portfolio and holding for a decade or longer might be all you need to realize significant gains.

REITs are ideal for investors who prioritize capital preservation and sustainable returns.

If you have a smaller investment portfolio, it's hard to get excited about dividend stocks. An extra 6% a year doesn't feel impactful when it is calculated against a small base. However, as your wealth grows, the dynamic switches, and compounding dividends start to look like an infinite money glitch.

For example, with $50,000 invested, a 6% yield gives you an extra $3,000 a year. With $1 million, it provides you $60,000 in annual passive income, which is more than the U.S. median income.

Let's explore some reasons why buying shares in Realty Income Corp. (O 0.32%) or Alpine Income Property Trust (PINE +1.67%) could be an excellent idea for long-term investors who have a lot of cash to work with.

Realty Income
Realty Income is part of a special class of companies called real estate investment trusts (REITs), designed to give investors access to the wealth-generating power of real estate. The structure requires the company to return the vast majority of profits to shareholders, leading to a large and steadily growing dividend payout. Meanwhile, its defensive and well-diversified business model allows large investors to sleep a little easier at night.

Today's Change

(

-0.32

%) $

-0.18

Current Price

$

56.49

While it can be tempting to chase market-beating returns in hyped-up new industries like generative artificial intelligence (AI) or quantum computing, these companies have a higher risk of failure, making them somewhat undesirable for investors who prioritize capital preservation. Income Realty offers exposure to more proven sides of the economy, like grocery stores, convenience stores, and automotive service shops.

Realty Income further reduces risk through triple-net leases, where the tenant is required to pay for property-level operating expenses like taxes, maintenance, and insurance. This strategy shields the REIT's cash flows from macroeconomic challenges like inflation, which tends to be relatively high in the real estate industry.

Realty Income's main selling point is its dividend yield, which now stands at 5.74% annually, broken into 12 monthly payments. This payout trounces the S&P 500's average of just 1.2%, and it probably won't stay this low forever. The Federal Reserve has started to lower interest rates. This trend benefits REITs because it makes it cheaper for them to borrow money for expansion, while also making their yields look more attractive relative to other income-generating securities like Treasury bonds.

Alpine Income
Realty Income is an excellent company for income-focused investors. But with a market cap of $52 billion, it is already one of the largest REITs in the world. And the larger a company becomes, the harder it is to drive future growth. Alpine Income is an excellent alternative because of its similar strategy and significantly smaller market cap of just $250 million.

Like Realty Income, Alpine Income focuses on single-tenant commercial income properties. It minimizes risks by prioritizing publicly traded clients like Lowe's, Dick's Sporting Goods, and Walmart. These types of companies tend to have higher credit ratings, stable customer bases, and tons of cash, making them much more reliable sources of income. Triple-net leases help protect the company from property-level operating costs.

Image source: Getty Images.

As a small company, Alpine Income faces some risk from client concentration. In the third quarter, Lowe's and Dick's Sporting Goods represented a whopping 22% of its annualized base rent. On the flip side, new deals can easily move the needle. And management continues to expand through deals, including the acquisition of three properties for $2.8 million in October. Falling interest rates will make it even easier for the company to buy new assets in the future.

Today's Change

(

1.67

%) $

0.28

Current Price

$

17.01

With a dividend yield of 7%, Alpine Income's dividend yield is remarkably high. And there is plenty of room for it to continue growing over time, making the stock an extremely attractive long-term buy.

Which dividend stock is better for you?
Realty Income and Alpine Income are both diversified REITs with big dividends. But they serve very different investment strategies. Realty Income is the better pick for safety-focused investors because of its larger size and long track record of success. Alpine Income is the riskier pick. But it is better for investors who prioritize growth potential.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

With these top tech stocks trading off their highs, now is a good time to buy.

Tech stocks have been helping to lead the market higher for much of the past two years, but many have taken a breather in recent weeks. That opens up an opportunity to grab some tech leaders trading off their highs.

Let's examine three leading tech stocks to consider buying before the end of the year.

Image source: Getty Images.

1. Taiwan Semiconductor Manufacturing
One of the companies best positioned for the ongoing artificial intelligence (AI) infrastructure boom is Taiwan Semiconductor Manufacturing (TSM +3.48%). While competition has increased in the AI chip race, with more companies turning to ASICs to run some of their AI workloads, TSMC remains in a prime position because it is the company that makes most of the world's advanced chips.

Today's Change

(

3.48

%) $

9.58

Current Price

$

284.64

Manufacturing advanced semiconductors is not easy, and TSMC has proven to be the only company that can consistently manufacture chips at smaller node sizes (the number of transistors that fit on a chip) with high yields (few defects) at scale. This has made it a key cog in the semiconductor value chain, leading to strong pricing power. It also gives it solid visibility, with the company projecting that AI chip demand will increase by a more-than-40% compound annual growth rate (CAGR) over the next few years.

2. Amazon
After getting a lift following a strong earnings report, Amazon's (AMZN +2.54%) stock finds itself right back to where it was before it posted its results. That's good news for investors looking to pick up some shares before year's end, as the company is starting to show solid momentum in its cloud computing business and strong operating leverage in its e-commerce operations.

Today's Change

(

2.54

%) $

5.60

Current Price

$

226.29

In Q3, Amazon's AWS (Amazon Web Services) unit saw its revenue growth accelerate to 20% on the back of strong demand for AI infrastructure and related services. However, this could just be the beginning of AWS's acceleration, as it has just started ramping up its big Project Rainier for Anthropic, while it also recently announced a seven-year, $38 billion deal with OpenAI. It also boosted its capital expenditure (capex) budget, raising it from $118 billion to $125 billion, to take advantage of the opportunities it is seeing.

At the same time, Amazon is using AI and robotics to drive efficiencies and profitability in its e-commerce business. It now has over 1 million robots in its fulfillment centers, all coordinated by its DeepFleet AI model, while it's also using AI to optimize driver routes and inventory locations. This is leading to strong operating leverage, as demonstrated by its North American segment's 28% jump in adjusted operating income last quarter on just an 11% increase in revenue.

3. Meta Platforms
Meta Platforms' (META +3.23%) stock has been punished recently for its aggressive AI spending plans, but that could be an opportunity for investors looking to buy the stock before the end of the year. Operationally, Meta is firing on all cylinders, with its revenue soaring 26% in Q3 on the back of increased ad impressions (up 14%) and higher ad prices (up 10%).

The company's growth is driven by its push into AI. Today, the company's sites are much more about entertainment than connecting with friends, and it's using AI to push more of the type of content that its users want to see, which is keeping them on its apps for longer. It's also helping it grow its daily active user base, which was up 7.5% to 3.54 billion last quarter.

Today's Change

(

3.23

%) $

19.21

Current Price

$

613.46

Meta is also using AI to help improve its advertisers' campaigns and better target users, which is leading to better-performing ads. This, in turn, is leading to higher prices. This dynamic is playing out not just in the U.S., where its average ad price climbed 13% last quarter, but also in Europe, where its price per ad jumped 17%.

The company also has a big opportunity in front of it, as it is just beginning to serve ads on its WhatsApp messaging service, which boasts over 3 billion users. In addition, it's still building out its newest social media platform, Threads, and just beginning to monetize that platform, as well.

Alibaba looks like a bargain compared to the top U.S. tech stocks.

Over the past few years, many American tech stocks skyrocketed to fresh record highs as the artificial intelligence (AI) market expanded. However, that secular boom also increased the weight of AI-driven tech stocks in the S&P 500 and stretched the benchmark index's valuations.

At 30 times earnings, the S&P 500 is trading far above its average price-to-earnings ratio of 20 over the past two decades. Therefore, investors shouldn't be too surprised if the market's bubblier tech stocks fizzle out and the market retreats to more sustainable levels.

Image source: Getty Images.

So instead of chasing the top U.S. tech stocks today, investors might want to pivot back toward the Chinese tech sector's unloved and undervalued stocks. Many of those companies are still growing and have wide moats, but their valuations are being compressed by the ongoing trade war between the U.S. and China.

One of those stocks is Alibaba (BABA +5.10%), China's top e-commerce and cloud infrastructure company. Alibaba's stock has already rallied about 80% this year, but it still trades about 50% below its all-time high and looks like a bargain at 18 times next year's earnings. Let's see why this stock could soar more than 70% over the next 12 months.

What happened to Alibaba over the past four years?
Alibaba was once considered a straightforward play on the rapid growth of China's e-commerce and cloud infrastructure markets. Its Taobao and Tmall marketplaces dominated online shopping as its Alibaba Cloud platform locked in big companies.

But in 2021, China's antitrust regulators cracked down on its e-commerce businesses. They hit it with a record $2.8 billion fine and barred it from locking in merchants with exclusive deals, using loss-leading promotions to gain new customers, and expanding its business with unapproved investments and acquisitions. Those tighter restrictions eroded its defenses against other e-commerce platforms, including PDD (PDD +0.22%) and JD.com (JD +0.45%).

To make matters worse, that crackdown coincided with China's post-pandemic economic slowdown, which was further exacerbated by its draconian "zero COVID" lockdowns. That pressure also drove many companies to rein in their spending on Alibaba's cloud infrastructure services.

Today's Change

(

5.10

%) $

7.80

Current Price

$

160.73

In fiscal 2022 (which ended in March 2022), Alibaba's revenue still rose 19%. But in fiscal 2023, its revenue grew just 2% as its core e-commerce and cloud engines stalled out. That slowdown convinced many investors that Alibaba's high-growth days were over.

Yet Alibaba's revenue rose 8% in fiscal 2024 and 6% in fiscal 2025 as its business gradually stabilized. To offset the sluggish growth of its Chinese e-commerce marketplaces, it expanded its higher-growth overseas marketplaces -- which include Lazada in Southeast Asia, Trendyol in Turkey, Daraz in South Asia, and AliExpress for its cross-border purchases. It also opened up its Cainiao logistics services to more external customers. Meanwhile, its cloud business recovered as more companies ramped up their spending on AI applications, and Alibaba integrated its own Qwen large language models into its cloud platform to support those newer AI services.

Why could Alibaba's stock rally more than 70%?
From fiscal 2025 to fiscal 2028, analysts expect Alibaba's revenue and earnings per share (EPS) to grow at a compound annual growth rate of 8% and 12%, respectively. That stable growth will probably be driven by its overseas e-commerce marketplaces, Cainiao, and Alibaba Cloud.

Assuming Alibaba still trades at 18 times forward earnings by the end of fiscal 2027 (March 2027) and the exchange rates remain stable, its stock could rise about 25%. But if it trades at a more generous 25 times forward earnings by then, its stock could rally roughly 73%.

We should take those estimates with a grain of salt, but Alibaba could easily command a higher valuation if the trade tensions between the U.S. and China finally ease. If that happens, Alibaba could outperform many of the top tech stocks in the U.S. over the next year.

MUMBAI, India--(BUSINESS WIRE)--Global investment firm KKR and Lighthouse Learning Group (“Lighthouse Learning”), a leading Indian education services provider, today announced an investment by funds managed by KKR alongside participation from a new investor, PSP Investments. KKR will continue to hold a majority stake and will play a significant role in driving Lighthouse Learning’s next phase of growth.

Guided by a ‘Child First’ philosophy and innovative teaching pedagogy, Lighthouse Learning is one of India’s leading education services platforms that operates in the early childhood and K-12 segments in India. Its portfolio of brands includes established and market leading brands such as EuroKids, Kangaroo Kids, EuroSchool, Billabong High International, Centre Point Group of Schools, Heritage International Xperiential School and Heritage Xperiential Learning School among others. Today, Lighthouse Learning nurtures more than 190,000 students daily through its over 1,850 preschools and 60 K-12 schools.

Since KKR’s initial investment in 2019, Lighthouse Learning has continued to deliver high quality education to students across the country, catering to the rising household demand for quality education. It has significantly expanded its footprint through organic and inorganic growth strategies, and strengthened its presence across key metropolitan areas, including Bangalore, Mumbai, Pune, Hyderabad and Delhi-NCR.

This latest investment will enable Lighthouse Learning to further expand its network of high-quality K-12 schools and preschools across key Indian cities. Lighthouse Learning will also continue to strengthen its teaching and technology capabilities, enhance operational excellence across the platform.

Akshay Tanna, Partner and Head of India Private Equity at KKR, said: “Lighthouse Learning has built one of the most trusted and respected education services platforms in India, combining academic quality with a strong reputation across its brands. We are proud of the growth that Lighthouse Learning has achieved in strategic partnership with KKR and are delighted to continue supporting their mission to expand access to high-quality education and nurture future generations of learners.”

Prajodh Rajan, Founder and Group CEO of Lighthouse Learning, said: “Education is a lifelong journey, and our mission has always been to deliver exceptional learning experiences that prepare students for a rapidly changing world. We are pleased to deepen our relationship with KKR as we enter this next chapter of growth. KKR’s long-term vision, global expertise, and deep commitment to education will help us scale our platform and continue to set new benchmarks for excellence across India’s education sector.”

KKR is making its investment predominantly from its Asian Fund IV and other KKR-managed capital.

About Lighthouse Learning Group

Lighthouse Learning Group, formerly known as EuroKids International, is India's leading Early Childhood & K-12 Education group, backed by global investment firm KKR. Driven by its purpose to unlock human potential by igniting the love for learning through its institutions, which includes leading brands like EuroKids Preschool, Kangaroo Kids Preschool, EuroSchool, Billabong High International, Centre Point Group of Schools, Heritage International Xperiential School, Heritage Xperiential Learning School, Phoenix Greens School of Learning and Finland International School Maldives. Nurturing over 190,000 students every day, Lighthouse Learning emphasizes a 'Child First' philosophy, innovative pedagogy, and child safety. With over 1,850 Preschools and 60 K-12 Schools, it empowers 1,500 women entrepreneurs and employs a direct and indirect workforce of over 22,000 people.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About PSP Investments

The Public Sector Pension Investment Board (PSP Investments) is one of Canada’s largest pension investors with $299.7 billion of net assets under management as of March 31, 2025. It manages a diversified global portfolio composed of investments in capital markets, private equity, real estate, infrastructure, natural resources, and credit investments. Established in 1999, PSP Investments manages and invests amounts transferred to it by the Government of Canada for the pension plans of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montréal and offices in New York, London and Hong Kong. For more information, visit investpsp.com or follow us on LinkedIn.

Poland's anti-monopoly office UOKiK is investigating whether Apple is restricting competition in the mobile advertising market through its privacy policy, it said on Tuesday.

-

Agreement sets stage for strengthened global reach, scalability, and resilience for fintechs and banks worldwide

LONDON--(BUSINESS WIRE)--Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing.

By committing to Visa Cloud Connect globally, we’re helping our clients gain faster, more resilient access to Visa’s network, while advancing our strategy to deliver a single, cloud-first global platform.

Share
Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders.

Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and accelerating Thredd’s vision of a unified global processing platform.

"Signing this agreement is about future-proofing payments infrastructure," said Jonathan Vaux, Head of Propositions and Partnerships at Thredd. "By committing to Visa Cloud Connect globally, we’re helping our clients gain faster, more resilient access to Visa’s network, while advancing our strategy to deliver a single, cloud-first global platform. Whether launching new programmes or scaling across markets, we strive to provide our clients with speed, reliability, and simplified expansion."

For Thredd, this agreement represents a significant step in its ongoing cloud transformation. It supports the company’s mission to provide clients with the most agile, scalable, and future-ready infrastructure in payments. This announcement builds on Thredd’s long-standing relationship with Visa and reflects a shared commitment to advancing cloud-based infrastructure in payments.

About Thredd

Thredd is the trusted, AI-first, cloud-enabled issuer processing platform powering the next generation of global payments. Through a single API, unified platform, Thredd delivers debit, credit, digital wallet and ledger capabilities to over 100 fintech, digital banks and embedded finance providers, across 47 countries, processing billions of transactions annually. With a global operating footprint, local expertise, and AI integrated into every layer of its platform, Thredd has been purpose-built for speed, scale and modern issuance models, setting the standard for market entry, client experience, security, regulatory rigour and operational resilience. Learn more at www.thredd.com

More News From Thredd

Back to Newsroom

Not for dissemination in the United States or through U.S. newswires --Drilling Reaches 400m Target Depth Testing IP Chargeability High VANCOUVER, BC / ACCESS Newswire / November 25, 2025 / Star Copper Corp. (CSE:STCU)(OTCQX:STCUF)(FWB:SOP) ("Star Copper" or the "Company"), is pleased to announce completion of the inaugural drill hole at its high‑impact Star North target, located approximately one kilometer northeast of the Star Main zone, within the Company's 100%‑owned Star Project, British Columbia. The Star North target mirrors the Star Main target in its geophysical and geochemical signature.

TORONTO , Nov. 25, 2025 /PRNewswire/ -- Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) is pleased to announce the voting results from its Annual General and Special Meeting ("AGSM") held on November 20, 2025 in Toronto, Ontario. Shareholders voted in favor of all items of business presented at the AGSM, as outlined in the proxy-related materials, including the Notice of Meeting and the Information Circular dated October 14, 2025 (the "Information Circular").

The electric vehicle maker is expanding its manufacturing footprint as it scales up.

Rivian (RIVN +2.09%) made waves when it went public in 2021. The stock captured investors' attention as support for electric vehicles (EVs) gained significant momentum, and people became optimistic about their growth potential. Fast forward to today, and Rivian's stock is down 92% from its all-time high price in 2021.

It's been a tough backdrop for EV stocks lately, with tailwinds from federal support waning. That said, Rivian boasts a growing lineup of all-electric vehicles, and it is expanding while working to achieve greater cost efficiencies. With the stock priced below $19 per share, is it a buy? Let's dive into the business and find out.

Rivian's growing vehicle and technology platform
Rivian takes a vertically integrated approach to its business, focusing on in-house manufacturing, which includes its proprietary technology platform and software stack. Many of Rivian's components are developed in-house in its Normal, Illinois, facility. This includes electric motors, gearboxes, battery packs, and vehicle electronics, among others.

Image source: Rivian.

Rivian aims to gain a competitive advantage through its technology platform and software stack. Its zonal network architecture and Electronic Control Units (ECUs) are the basis for the vehicle's electrical system. With its full vehicle software stock, Rivian can control and enhance different aspects of the vehicle's software, digital experience, and driving dynamics.

Today's Change

(

2.09

%) $

0.31

Current Price

$

15.17

It also has the Rivian Autonomy Platform, which integrates machine learning and artificial intelligence (AI). Rivian views autonomy as a critical area for transportation and a crucial component for its future sales. Rivian plans to expand its software offerings to include the Rivian Autonomy Platform+, a premium expansion of its automated driver assistance capabilities.

Improving cost structure by scaling manufacturing
One key area for Rivian is its financials. Last year, the automaker lost $4 billion in operations through the first nine months. The company has made some progress this year, shrinking its loss from operations to $2.75 billion through Sept. 30.

Its long-term cost-reduction strategy centers on the development and launch of the Midsize Platform, which underpins the R2 and R3 vehicle lines. This platform is designed to reduce manufacturing complexity and improve cost efficiency compared to the current R1 platform.

Increasing manufacturing volume and optimizing plant operations are other ways it aims to reduce the fixed cost per vehicle. Its future profitability depends on its ability to scale production and delivery operations more efficiently at a lower cost per unit.

RIVN Revenue (TTM) data by YCharts

It currently manufactures vehicles on the R1 and Rivian Commercial Van platforms at its Normal facility, with an installed capacity of up to 150,000 vehicles annually. It plans to integrate the production of its upcoming midsize platform, starting with the R2 vehicle, into the facility.

To prepare for this, upgrades were completed in early October 2025, increasing the total annual plant capacity to 215,000 units. The expanded capacity is expected to be up to 155,000 R2 vehicles, alongside 85,000 R1 vehicles and 65,000 commercial vans. This expansion is expected to lower the fixed cost per vehicle.

A second manufacturing facility, the Stanton Springs North Facility near Social Circle, Georgia, is planned to support demand from the United States and international markets. Construction is expected to begin in 2026, with production anticipated to start on the first manufacturing line in 2028. This facility, designed for an anticipated annual capacity of 400,000 vehicles, is being built in two phases.

Is Rivian a buy?
Rivian is scaling up its business, expanding its platform, and growing its offerings. The company is making progress on improving its costs and bottom-line profitability. Scaling up should help it achieve better economies of scale and improve its profitability and bottom line.

The company noted material cost reductions and a reduced impact from tariffs in the third quarter, which decreased from "a few thousand" per vehicle to "a few hundred." Management expects these savings to extend to its R2 platform and aims to achieve positive gross margins by late 2026.

Rivian is performing well despite the challenging backdrop and headwinds from reduced federal support for EVs, which could impact demand. The company is making progress on improving its cost structure, and its new R2 SUV is expected to boost sales and deliveries next year. With that said, I'd like to see further progress on its bottom line before buying the stock.

November 25, 2025 3:05 AM EST | Source: First Hydrogen Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2025) - First Hydrogen Corp. (TSXV: FHYD) (OTC Pink: FHYDF) (FSE: FIT) ("FIRST HYDROGEN" or the "Company")  announces the start of focused technical research to identify and recommend non-radioactive surrogate molten-salt fuel mixtures for use in future lab-scale protypes. This initial phase marks the beginning of the design, design optimization and reactor fuel materials for small nuclear reactors (SMRs) project with the University of Alberta lead by Prof. Muhammad Taha Manzoor. The outcome of this research will guide First Hydrogen's next research and development (R&D) steps, including lab setup, test planning, and supplier engagement.

First Hydrogen and its technical advisors will undertake a comprehensive review and consultative process to select candidate surrogate mixtures that mimic the thermophysical behavior of uranium-bearing fuel salts and a base molten salt mixture. The research will prioritize mixtures suitable for near-term lab evaluation and early prototype development-without the use of uranium in this phase-ultimately advancing First Hydrogen's commercial scale-up objectives. Prof. Manzoor's team will conduct a detailed analysis to identify the most suitable molten-salt mixtures for SMRs and access their availability and procurement options, including potential supplies, tariffs, export controls and the other regulatory requirements.

Molten-salt fuels have attracted growing interest for their ability to deliver safe, efficient, and flexible nuclear energy. Unlike conventional solid fuel rods, fuel dissolved in molten salts can circulate through a reactor core, allowing for more efficient heat transfer and inherently safer operating conditions. These salts remain stable at high temperatures and low pressures, reducing the risk of high-pressure accidents and enabling smaller, modular reactor designs.

Dr. Manzoor commented, "We are excited to officially kick-start this project on molten salt fuels with First Hydrogen. We intend to bring in world-class researchers and incorporate low-hazard approaches into our lab-scale experimentation while supporting First Hydrogen's future objectives for molten salt fuels in SMRs."

"This non-radioactive work helps us de-risk future R&D by identifying practical surrogate salts for lab prototypes. It is the first step that aligns with our longer-term vision of pairing firm, clean energy for data centres, AI, green hydrogen production while also providing a source of fuel for use in all SMRs," commented Balraj Mann CEO of First Hydrogen.

In the International Energy Agency's (IEA) report titled, "Energy and AI", the IEA estimates that data centre electricity consumption will more than double, growing from 415 terawatt-hours (TWh) in 2024 to 945 TWh by 2030. The need for electricity will be driven by a significant change in the capabilities of artificial intelligence (AI) fueled by falling computation costs, a surge in data availability and technical breakthroughs. (IEA (2025), Energy and AI, IEA, Paris https://www.iea.org/reports/energy-and-ai, Licence: CC BY 4.0)

For further information, please contact:
First Hydrogen Corp.
Investor Relations
Email: [email protected]
Website: www.firsthydrogen.com

About First Nuclear Corp. (FirstNuclear.com)
First Nuclear Corp. is committed to developing and commercializing advanced clean energy solutions, including green hydrogen produced by state-of-the-art Small Modular Reactors. The Company aims to provide scalable, sustainable, and economically viable alternatives to meet global climate goals and enhance energy security.

About First Hydrogen Corp. (FirstHydrogen.com)
First Hydrogen Corp. is a Vancouver, Montreal, Germany and London UK-based company focused on zero-emission vehicles, green hydrogen production and distribution. The Company has designed and built two hydrogen- fuel-cell-powered light commercial vehicles ("FCEV"). The FCEV are road-legal in the United Kingdom (excluding Northern Ireland) with 6,000 km of testing completed and have achieved a range of 630+ kilometres on a single refueling. The vehicles have successfully been trialled in real-world conditions with fleet operators in the United Kingdom.

On behalf of the Board of Directors of

FIRST HYDROGEN CORP.
"Balraj Mann"
Chairman & Chief Executive Officer

Cautionary Note Regarding Forward-Looking Statements This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of First Hydrogen, and includes statements about, among other things, future developments and the future operations, strengths and strategies of First Hydrogen. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for First Hydrogen's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of First Hydrogen as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. First Hydrogen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275804

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MNDY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Kingfisher operates retail brands such as B&Q and Screwfix. phil noble/ReutersKingfisher lifted its profit outlook for fiscal 2026, saying its performance to date and cost savings give it confidence despite weakening market conditions in the U.K. and Poland.

The U.K. home-improvement retailer now expects adjusted pretax profit for the year ending Jan. 31 to range from 540 million to 570 million pounds ($707.7 million-$747 million). It had previously forecast a result at the upper end of the 480 million to 540 million pound range.

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

A new wave of growth may be just ahead.

Growth stocks, particularly in the industry of technology, have helped the S&P 500 roar higher in recent years, climbing in the double digits in 2023 and 2024 -- and now, the benchmark is heading for yet another double-digit increase in 2025. Considering this, you may think that it's too late to get in on growth stocks -- that they're either too expensive today or have reached their earnings and stock performance peaks.

But I have some good news for you. Many growth stocks remain reasonably priced and continue to offer fantastic long-term prospects. One, in particular, stands out, though, thanks to its established track record in two major industries and signs that show another wave of growth taking shape. With $1,000, or even much less, you can scoop up shares of this consumer goods and tech giant. Let's find out more.

Image source: Getty Images.

A company you may know well
You may be familiar with this company as you might turn to it daily for your groceries or general shopping, or you might rely on it for entertainment, such as books and movies. I'm talking about Amazon (AMZN +2.54%). The company is an e-commerce powerhouse, generating billions of dollars in revenue quarter after quarter, but it also is the world's biggest cloud service provider through its Amazon Web Services (AWS) business.

Together, these businesses are driving growth at Amazon, and much more may be on the horizon. This is because Amazon has made and is making a variety of efforts to streamline its operations and supercharge growth -- and these are producing tremendous results.

Today's Change

(

2.54

%) $

5.60

Current Price

$

226.29

Amazon, a few years ago, redesigned its cost structure, an effort that's lowered its cost to serve and is boosting profitability. This included the major move of shifting its fulfillment network to a regional model from a national one -- inventory is therefore closer to the customer, resulting in speed and lower delivery costs for the company.

Amazon is set to reach its fastest delivery speeds ever this year, and the company is making moves to win in rural areas, for example, investing $4 billion to strengthen its delivery network -- these small towns generally are underserved, so they could represent a key growth area.

Using AI in e-commerce
The company also has integrated artificial intelligence (AI) into the e-commerce experience, with the shopping assistant Rufus, and uses AI to further streamline the fulfillment process. All of this pleases customers, encouraging them to come back, and supports earnings growth. Monthly users of Rufus have soared 140% year-over-year, Amazon said in the recent quarter -- and shoppers using this AI assistant are 60% more likely to make a purchase.

Now, speaking of AI, the technology already is driving significant gains for AWS. It's important to keep in mind that AWS dominates the cloud service market and, therefore, is well-positioned to lead in AI. Since companies' data, to a great degree, already are on AWS, it's not surprising that many of these customers are turning to AWS for AI too.

AWS offers these customers an enormous variety of AI options -- from top Nvidia chips to Amazon-developed chips for the more cost-conscious customer and a fully managed AI service called Amazon Bedrock. Customers can rely on AWS for all of their AI projects, including basics like the training of models to actually applying AI to their needs using AI agents.

Reigniting growth
All of this has helped reignite AWS' growth, with the unit delivering its fastest growth rate in 11 quarters in the most recent period. AWS revenue jumped more than 20% year-over-year, and the unit's annualized revenue run rate reached $132 billion. And a fresh wave of growth may lie ahead as customers continue to pile into AI products and services.

Of course, Amazon does face some headwinds. U.S. import tariffs on goods could weigh on earnings, and any dip in consumer confidence might hurt demand for discretionary purchases. As for AWS, though it's a leader, it still faces cloud competition from other giants like Microsoft as well as smaller AI-focused players like CoreWeave. Still, I wouldn't expect these challenges to pose significant problems for Amazon over the long term.

And right now, Amazon offers investors a clear opportunity. The stock trades for 31x forward earnings estimates, a very reasonable level for a market leader winning in the growth areas of e-commerce, cloud services, and AI. All of this makes Amazon the ultimate growth stock to buy right now with $1,000 or even less -- and hold onto for the long haul.

About Oliver Haill
Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup News Service, Gracenote... Read more

About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.

Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.

The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.

Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.

Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.

Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

Australian food delivery workers are on course to gain minimum pay levels after Uber Eats and DoorDash struck a deal with the country's transport union that is being hailed as a world first.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Q4: 2025-11-24 Earnings SummaryEPS of $1.59 beats by $0.01

 |

Revenue of

$1.86B

(9.41% Y/Y)

beats by $28.50M

Agilent Technologies, Inc. (A) Q4 2025 Earnings Call November 24, 2025 4:30 PM EST

Company Participants

Tejas Savant
Padraig McDonnell - CEO, President & Director
Adam Elinoff - Senior VP, CFO & Principal Financial Officer
Rodney Gonsalves - Principal Accounting Officer, VP & Corporate Controller
Simon May - SVP & President of LDG
Angelica Riemann - Senior VP & President of Agilent CrossLab Group
Mike Zhang - Senior VP & President of Applied Markets Group

Conference Call Participants

Tycho Peterson - Jefferies LLC, Research Division
Patrick Donnelly - Citigroup Inc., Research Division
Daniel Leonard - UBS Investment Bank, Research Division
Douglas Schenkel - Wolfe Research, LLC
Brandon Couillard - Wells Fargo Securities, LLC, Research Division
Vijay Kumar - Evercore ISI Institutional Equities, Research Division
Jack Meehan - Nephron Research LLC
Daniel Brennan - TD Cowen, Research Division
Michael Ryskin - BofA Securities, Research Division
Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division
Casey Woodring - JPMorgan Chase & Co, Research Division
Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division
Luke Sergott - Barclays Bank PLC, Research Division

Presentation

Operator

Good afternoon. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Agilent Technologies, Inc. Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Thank you.

Tejas, you may begin the conference.

Tejas Savant

Thank you, and welcome, everyone, to Agilent's conference call for the fourth quarter of fiscal year 2025. As many of you know, I recently joined Agilent after a fun 15-year stint on Wall Street and I'd just like to say how excited I am to be joining the team at such a pivotal time in our journey.

With me on the line are President and CEO, Padraig McDonnell; CFO, Adam Elinoff; and Rodney Gonsalves, Vice President, Controller and Principal Accounting Officer, who served as interim CFO until Adam's arrival.

Recommended For You

Best Buy Co., Inc. (NYSE:BBY) will release earnings results for the third quarter, before the opening bell on Tuesday, Nov. 25.

Analysts expect the New Albany, Ohio-based company to report quarterly earnings of $1.31 per share, up from $1.26 per share in the year-ago period. The consensus estimate for Best Buy's quarterly revenue is $9.59 billion. Benzinga Pro data shows $9.45 billion in quarterly revenue a year ago.

During the second-quarter earnings call, CFO Matt Bilunas guided for third-quarter comparable sales to mirror the 1.6% growth seen in the previous quarter, signaling that the company is trending toward the higher end of its full-year revenue guidance of $41.1 billion to $41.9 billion.

Shares of Best Buy fell 1.1% to close at $75.62 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating with a price target of $90 on Nov. 18, 2025. This analyst has an accuracy rate of 65%.
JP Morgan analyst Christopher Horvers maintained an Overweight rating and raised the price target from $89 to $97 on Nov. 14, 2025. This analyst has an accuracy rate of 72%.
Truist Securities analyst Scot Ciccarelli maintained a Hold rating and increased the price target from $72 to $79 on Nov. 7, 2025. This analyst has an accuracy rate of 70%.
Argus Research analyst Chris Graja maintained a Hold rating on Sept. 16, 2025. This analyst has an accuracy rate of 66%.
Wedbush analyst Alicia Reese maintained a Neutral rating and raised the price target from $70 to $75 on Aug. 29, 2025. This analyst has an accuracy rate of 66%
Considering buying BBY stock? Here’s what analysts think:

Read This Next:

Jim Cramer: This Tech Stock Is ‘Losing Too Much Money’, Recommends Buying Mettler-Toledo
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Independent review validates Qastle's integration of Quantum eMotion's QRNG2 engine and alignment with NIST, OWASP, and PTES security frameworks
November 25, 2025 12:53 AM EST | Source: Krown Technologies LLC
Monroe, Louisiana--(Newsfile Corp. - November 25, 2025) - Krown Technologies, Inc., developer of the Krown Network and the Qastle quantum-secured hot wallet, today announced the findings of a comprehensive security assessment of the Qastle application suite and its integration with Quantum eMotion's QRNG2 quantum entropy engine. The assessment confirms the validity, viability, sustainability, and operational robustness of QRNG2 within Qastle's key-generation and wallet-creation workflows.

The Qastle Security Assessment concludes that Qastle's end-to-end architecture-mobile apps, API layer, and browser extensions-has been designed and implemented with a strong focus on protecting private keys, safeguarding user data, and securing all transaction flows.

QRNG2: True Quantum Entropy at the Core of Qastle

Within Qastle, entropy for cryptographic material is sourced directly from Quantum eMotion's QRNG2 engine through a tightly integrated API workflow. Each time Qastle needs randomness for key creation, it issues a call to the QRNG endpoint to retrieve a truly non-deterministic quantum value, rather than relying on traditional pseudo-random generators. Every call is logged with timestamps, response status, and system state, and transient failures trigger controlled retries until a valid quantum value is obtained.

All QRNG2 interactions and related logs are stored in a containerized infrastructure that provides isolation, integrity controls, and traceability. This design allows Krown's engineering team to verify that quantum entropy was requested, received, and correctly applied in the wallet-generation process, providing strong assurance that QRNG2 is operating as intended and sustaining its performance over time.

"We set out to prove-not just claim-that Qastle is driven by real quantum entropy," said James Stephens, Chief Executive Officer of Krown Technologies, Inc. "This assessment validates that Quantum eMotion's QRNG2 engine is not only viable, but operationally robust and sustainable in live production conditions. Every wallet that Qastle generates is backed by true quantum randomness, documented with auditable logs, and aligned with the highest standards of modern cybersecurity."

Built on NIST, OWASP, and PTES Security Frameworks

The Qastle assessment was conducted using globally recognized security frameworks, including the NIST Cybersecurity Framework, the OWASP methodology, and the Penetration Testing Execution Standard (PTES). NIST's Framework provides structured guidance to help organizations identify, protect, detect, respond to, and recover from cyber threats, while OWASP and PTES together define rigorous approaches to application security testing and penetration testing.

For Qastle iOS and Android, the review addressed cryptographic implementations, secure storage of sensitive material, application hardening, transport-layer security, and resilience against tampering and reverse-engineering. For the Qastle API, the assessment focused on endpoint-level controls, authentication and authorization flows, input validation, rate limiting, and session management. The browser extensions were reviewed for permissions, data-access boundaries, and message-passing behavior to ensure least-privilege operation and safe interaction with both the local environment and Qastle's backend.

"From the outset, Qastle was engineered to be a security-first wallet," said Gareth Slaven, Chief Technology Officer at Krown Technologies, Inc. "This assessment confirms that our architecture, our use of QRNG2, and our operational processes align with NIST, OWASP, and PTES best practices. Just as important, it confirms that QRNG2 behaves flawlessly in our production stack-delivering reliable, quantum-grade entropy without compromising performance or user experience."

Validating Viability, Sustainability, and Operational Flow

Beyond point-in-time testing, the assessment emphasizes Qastle's ability to sustain secure operations over time. Detailed logging of QRNG2 calls, containerized infrastructure, and robust error-handling flows demonstrate that the integration is not only technically sound, but operationally resilient.

By combining quantum-grade entropy with layered application security, Qastle is positioned to operate securely at scale as the number of users, transactions, and supported assets continues to grow. This security posture helps Qastle address today's attack landscape while preparing for emerging quantum and classical threats in the years ahead.

Path Toward NIST Certification

With the successful validation of Qastle's security posture and the confirmed operational integrity of Quantum eMotion's QRNG2 entropy engine, Krown Technologies is now preparing for its next milestone: formal NIST certification. The assessment demonstrates strong adherence to NIST's Cybersecurity Framework principles, and Krown's engineering team has already initiated the internal mapping required for certification readiness.

This next phase will involve expanding Qastle's documented controls, strengthening audit trails, and engaging with certified NIST evaluators to validate the architecture against official standards for cryptographic modules, entropy sources, and secure application processes. The move positions Qastle-and the broader Krown Network-to become one of the world's first quantum-secured wallet environments aligned with formal federal standards for cybersecurity.

"Our goal is clear: we intend for Qastle to meet and ultimately achieve NIST-grade certification," said James Stephens, CEO of Krown Technologies, Inc. "This is a natural progression after the outstanding performance demonstrated in our QRNG2 integration assessment. We are building technology for a world that demands provable, measurable, and certified security."

About Qastle Wallet

Qastle is a next-generation, quantum-secured hot wallet developed by Krown Technologies, Inc. It integrates Quantum eMotion's QRNG2 engine to deliver true quantum entropy for key generation, combined with a security architecture aligned to NIST, OWASP, and PTES frameworks. Qastle is designed to provide everyday users and institutions with a secure, intuitive wallet experience that anticipates the coming quantum era of cybersecurity.

About Krown Technologies, Inc. / Krown Network

Krown Technologies, Inc., headquartered at 201 Victory Blvd., Monroe, Louisiana, is the company behind the Krown Network and the broader Camelot ecosystem-an expanding suite of blockchain, DeFi, AI, and security products focused on delivering quantum-secured infrastructure for digital assets. Krown's mission is to build one of the world's most secure and rewarding blockchain ecosystems for users, builders, and institutions alike.

About Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0)

Quantum eMotion Corp. is a Canadian deep-tech company commercializing Quantum Random Number Generator (QRNG) solutions for cybersecurity, blockchain, and fintech. Its QRNG2 hardware produces true quantum entropy to secure data and transactions against classical and post-quantum threats.
Website: https://quantumemotion.com.

Forward-Looking Information

This release may contain forward-looking statements relating to user adoption, revenue forecasts, and market growth. Actual results may differ due to factors beyond the control of Krown Technologies and Quantum eMotion.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275853

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo

In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment

Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU

TARRYTOWN, N.Y. and PARIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. Eligible patients can use Dupixent as a first-line targeted treatment option.

“The unpredictable nature of chronic spontaneous urticaria leaves patients guessing when they’ll have their next outbreak of disruptive, debilitating hives and itch, which can make life challenging,” said Tonya Winders, President & CEO, Global Allergy & Airways Patient Platform. “Dupixent is proven to reduce these intense symptoms and has the potential to make a positive impact on people struggling to control this disease.”

“The approval of Dupixent for certain adults and adolescents with chronic spontaneous urticaria in the European Union represents the first innovation for patients with this disease in over a decade,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Physicians now have a new approach for CSU with Dupixent, as the only treatment that inhibits IL-4 and IL-13, two key drivers of type 2 inflammation, and can offer patients significant improvement in debilitating itch and hives. This approval further demonstrates the ability of Dupixent to advance the treatment landscape for yet another chronic type 2 inflammatory disease, with a well-established safety profile across its indications.”

The approval is based on data from two Phase 3 clinical trials in the LIBERTY-CUPID program. Study A and Study C included 284 patients aged 12 years and older who were symptomatic despite the use of antihistamines and who were naïve to anti-IgE therapy. Both trials assessed Dupixent as an add-on therapy to standard-of-care antihistamines compared to antihistamines alone and demonstrated Dupixent significantly reduced urticaria activity (a composite of itch and hives), and individual measures of itch and hive severity compared to placebo at 24 weeks. Dupixent also increased the percentage of patients with well-controlled disease and complete response at 24 weeks compared to placebo. Study B included 108 patients and provided additional safety data and evaluated Dupixent in patients aged 12 years and older who were inadequate responders or intolerant to anti-IgE therapy and symptomatic despite antihistamine use.

Safety results from Study A, Study B and Study C were generally consistent with the known safety profile of Dupixent in its approved indications. The most common adverse reactions for Dupixent overall are injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. Additional adverse reactions of injection site induration, injection site dermatitis and injection site hematoma were reported in the CSU adult and adolescent trials. Adverse events more commonly observed with Dupixent (≥5%) than placebo in patients with CSU were injection site reaction, COVID-19, hypertension, CSU and accidental overdose.

“Standard-of-care, first-line treatment options like antihistamines offer limited relief for many people living with uncontrolled chronic spontaneous urticaria, leaving them to face unrelenting cycles of itch and hives,” said Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology Development at Sanofi. “Dupixent significantly reduced these symptoms of CSU and led to more patients experiencing well-controlled disease or a complete response compared to placebo in two Phase 3 studies. Now, eligible patients with CSU in the EU have a new option that is proven to reduce itch and hives.”

Beyond the European Union (EU), Dupixent is also approved for CSU in certain adults and adolescents in several countries including the United States and Japan.

About CSU
CSU is a chronic, inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch. CSU is typically treated with H1AH, medicines that target H1 receptors on cells to control symptoms of itch and urticaria. However, the disease remains uncontrolled despite H1AH treatment in many patients, some of whom are left with limited alternative treatment options. These individuals continue to experience symptoms that can be debilitating and significantly impact their quality of life. More than 270,000 people in the EU aged 12 years and older suffer from CSU that is inadequately controlled by antihistamines.

About the Dupixent CSU Phase 3 Trial Program
The LIBERTY-CUPID Phase 3 program evaluating Dupixent for CSU consists of Study A, Study B and Study C. These trials were randomized, double-blind, placebo-controlled clinical trials that evaluated the efficacy and safety of Dupixent as an add-on therapy to standard-of-care antihistamines compared to antihistamines alone. Studies A and C were replicate trials that assessed patients aged 6 years and older who remained symptomatic despite the use of antihistamines and were naïve to anti-IgE therapy. Study B was conducted in patients aged 12 years and older who were symptomatic despite use of antihistamines and were inadequate responders or intolerant to anti-IgE therapy. During the 24-week treatment period in all three trials, all patients received an initial loading dose followed by either 300 mg Dupixent every two weeks or 200 mg every two weeks for adolescents weighing <60 kg.

The primary endpoint in all three studies assessed the change from baseline in itch and hives (weekly urticaria activity score [UAS7], 0-42 scale). The key secondary endpoint (also assessed at 24 weeks) was change from baseline in itch (measured by the weekly itch severity score [ISS7], 0-21 scale). Additional secondary endpoints assessed at 24 weeks evaluated:

Change from baseline in hives (measured by the weekly hive severity score [HSS7], 0-21 scale)Proportion of patients achieving well-controlled disease status (UAS7 ≤6)Proportion of patients with complete response (UAS7=0).
The results from Studies A and B were published in The Journal of Allergy and Clinical Immunology. 

About Dupixent
Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with CSU who remain symptomatic despite H1AH treatment, Dupixent 300 mg is administered every two weeks after an initial loading dose. In patients aged 12 to 17 years with CSU who remain symptomatic despite H1AH treatment, Dupixent is administered every two weeks based on weight (200 mg for adolescents ≥30 to <60 kg, 300 mg for adolescents ≥60 kg) after an initial loading dose. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. In adolescents aged 12 to 17 years, Dupixent should be administered under the supervision of an adult.

Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD) and bullous pemphigoid (BP) in different age populations. More than 1,300,000 patients are being treated with Dupixent globally.1

About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

Dupilumab Development Program
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. 

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, lichen simplex chronicus and allergic fungal rhinosinusitis. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. 

U.S. INDICATIONS 
DUPIXENT is a prescription medicine used:

to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age. DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

have eye problems.have a parasitic (helminth) infection.are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, or BP and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.
The most common side effects include:

Eczema: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).Prurigo Nodularis: eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.Chronic Spontaneous Urticaria: injection site reactions.Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.  

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY 

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria in adults and adolescent patients 12 years and above; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, allergic fungal rhinosinusitis, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Sanofi Disclaimers or Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

__________________

1 Data on File

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trialKisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast cancer patients Basel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium® (SABCS). Featured among these latest advances in hematology and oncology are 11 oral presentations, with the Phase III VAYHIT2 trial for ianalumab in immune thrombocytopenia (ITP) accepted as a late-breaker abstract.

“For decades, Novartis has redefined the future of hematology and oncology, and we’re building on that foundation with compelling new data presented at ASH and SABCS,” said Mark Rutstein, M.D., Global Head, Oncology Development, Novartis. “These data underscore how we seek to set new standards for transformative care, with the aim of turning cutting-edge innovation into meaningful impact for patients.”

Key highlights of data accepted by ASH include:

Abstract Title Abstract Number/ Presentation Details Ianalumab (VAY736)Primary results from VAYHIT2, a randomized, double-blind, Phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract #LBA-2
Oral Presentation
December 9, 7:45 – 8:00 am ETSecondary analysis results from VAYHIT3, a Phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapyAbstract #844
Oral Presentation
December 8, 3:30 – 3:45 pm ETScemblix® (asciminib)Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysisAbstract #1997
Poster Presentation
December 6, 5:30 – 7:30 pm ETImproved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trialAbstract #5549
Poster Presentation
December 8, 6:00 – 8:00 pm ETAsciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)Abstract #906
Oral Presentation
December 8, 4:00 – 4:15 pm ETA comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phaseAbstract #724
Oral Presentation
December 7, 5:15 – 5:30 pm ETPelabresib (DAK539)Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 studyAbstract #910
Oral Presentation
December 8, 3:30 – 3:45pm ETRapcabtagene autoleucel (YTB323)Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: phase II interim resultsAbstract #670
Oral Presentation
December 7, 5:15 – 5:30 pm ETFabhalta® (iptacopan)Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dL on anti-C5 therapy: Subgroup analysis of the APPULSE-PNH Phase 3b trialAbstract #4981
Poster Presentation
December 8, 6:00 – 8:00 pm ETLong-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from phase 2 studies who entered the roll-over extension programAbstract #3198
Poster Presentation
December 7, 6:00 – 8:00 pm ETThe 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension programAbstract #4978
Poster Presentation
December 8, 6:00 – 8:00 pm ET Key highlights of data accepted by SABCS include:

Kisqali® (ribociclib)Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)Abstract # PD5-10
Poster Spotlight Presentation
December 11, 8:09 – 8:12 am CSTFive-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)Abstract # PS3-09-08
Poster Presentation
December 11, 12:30 – 2:00 pm CSTProgression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor–positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC) Abstract # PS1-10-27
Poster Presentation
December 10, 12:30 – 2:00 pm CSTRibociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patientsAbstract # PS3-09-15
Poster Presentation
December 11, 12:30 – 2:00 pm CSTReal-world patient (pt) and caregiver experiences with breast cancer (BC) risk of recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis Abstract # PS1-04-17
Poster Presentation
December 10, 12:30 – 2:00 pm CSTRepower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth fact receptor 2-negative (HER2−) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET) Abstract # PS3-08-27
Poster Presentation
December 11, 12:30 – 2:00 pm CST Product Information

For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.

Novartis in hematology
Our legacy in hematology runs deep, shaped by over 25 years of progress, partnerships and a commitment to keep asking questions, challenging norms and striving for better answers in a uniquely complex field. In the past two decades, we have delivered more than 10 medicines across more than 15 blood cancers and serious blood disorders including leading the era of targeted therapies in cancer and bringing the first CAR-T therapy to patients.

Innovation in hematology has brought significant progress, yet patients and clinicians continue to face persistent challenges. We’re forging the future of hematology, powered by our foundation in scientific discovery to deliver meaningful change for patients with unmet needs.

Novartis in breast cancer 
For over 30 years, Novartis has been at the forefront of driving scientific advancements for individuals affected by breast cancer and enhancing clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis leads the industry in discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #